Trial Report Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study 2024 Bested+

Discussion in ''Conditions related to ME/CFS' news and research' started by Andy, Jul 23, 2024 at 6:39 PM.

  1. Andy

    Andy Committee Member

    Messages:
    22,435
    Location:
    Hampshire, UK
    Abstract

    Introduction:
    Fibromyalgia (FM) is a chronic fluctuating, nociplastic pain condition. Naltrexone is a µ-opioid-receptor antagonist; preliminary studies have indicated a pain-relieving effect of low-dose naltrexone (LDN) in patients with FM. The impetus for studying LDN is the assumption of analgesic efficacy and thus reduction of adverse effects seen from conventional pharmacotherapy.

    Objectives:
    First, to examine if LDN is associated with analgesic efficacy compared with control in the treatment of patients with FM. Second, to ascertain the analgesic efficacy of LDN in an experimental pain model in patients with FM evaluating the competence of the descending inhibitory pathways compared with controls. Third, to examine the pharmacokinetics of LDN.

    Methods:
    The study used a randomized, double-blind, placebo-controlled, crossover design and had a 3-phase setup. The first phase included baseline assessment and a treatment period (days −3 to 21), the second phase a washout period (days 22–32), and the third phase a baseline assessment followed by a treatment period (days 33–56). Treatment was with either LDN 4.5 mg or an inactive placebo given orally once daily. The primary outcomes were Fibromyalgia Impact Questionnaire revised (FIQR) scores and summed pain intensity ratings (SPIR).

    Results:
    Fifty-eight patients with FM were randomized. The median difference (IQR) for FIQR scores between LDN and placebo treatment was −1.65 (18.55; effect size = 0.15; P = 0.3). The median difference for SPIR scores was −0.33 (6.33; effect size = 0.13; P = 0.4).

    Conclusion:
    Outcome data did not indicate any clinically relevant analgesic efficacy of the LDN treatment in patients with FM.

    Open access, https://journals.lww.com/painrpts/f...se_naltrexone_for_treatment_of_pain_in.3.aspx
     
    Simon M, oldtimer, Jaybee00 and 12 others like this.
  2. shak8

    shak8 Senior Member (Voting Rights)

    Messages:
    2,311
    Location:
    California
    RedFox, SNT Gatchaman, Hutan and 7 others like this.
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    28,035
    Location:
    Aotearoa New Zealand
    I like their diligent use of double blinding. In fact, I liked a lot about this study. It gives the impression of being very credible. I think the conclusion has to be that LDN is of no use for fibromyalgia - although perhaps some people will argue that the chosen standard dose doesn't work for many people. Edit - and some people think that a longer treatment period is required to see benefits.

    It is by a Danish team.

    I would have liked to have seen an examination of whether the timing of the active LDN arm (that is, in the first part of the crossover trial or the second) made any difference. It might have been there but I missed it in my read through.

    They replaced dropouts, and I didn't see how many dropouts there were.
     
    Last edited: Jul 24, 2024 at 6:07 AM
    forestglip, Dolphin, Simon M and 5 others like this.

Share This Page